A private commodities-investing Discord community (uranium-focused) — a channel-level archive of substantive member research shared in the #general channel. Stances are attributed to the named member in each note (e.g. William H. Hastings, a retired oil & gas executive whose emails are relayed to the channel with permission). Community-sourced diligence, not a single pundit's thesis.
Aggregated across posts; each ticker links up to the consolidated per-security page. Because this is a community channel, the "Current thesis" names which member held which view. Newest mention first.
A bundle of isotope businesses reaching first revenue together, now documented from both sides of the table on 20-AUG-2026: Frodsham2866's readout of a private Red Chip call, and CEO Paul Mann's own Emerging Growth Conference presentation (management framing — the company's pitch, not a member's view), which agree on every overlapping figure. Renergen's Virginia helium/LNG plant started up that week with first shipments due September and nameplate by Q4; Si-28 is enriching on 48 of an eventual 96–100 stages after a Swiss supplier's faulty compressor O-rings were root-caused and rebuilt (80 kg/yr at 99.995%, several hundred kg at 99%); Yb-176 reaches ~1 kg/yr once September's continuous vessel is built, into a market Russia alone supplies; PET Labs grew revenue >50% in H1 with revenue set to double in 2026 and AlphaNostics entering the clinic; and QLE is to be spun out by year-end. Group guidance: $300m EBITDA in 2031, a headline sitting below the sum of its own divisional low ends.
Ultra-low-cost (~A$200k) helium & natural-gas wells on the Virginia Fault corridor, Free State South Africa: a 479,409-acre position, independently verified helium up to 8%, a $600+/mcf product, and Sproule-certified reserves poised to migrate Contingent→Proven/Probable/Possible as the Nooitgedacht wells and the 2D seismic land. William H. Hastings is "strongly positive" — his wellhead-only matrix puts payout near one month.
PET Labs Pharmaceuticals — ASP Isotopes' nuclear-medicine unit (South Africa), incl. AlphaNostics
ASP Isotopes' South African nuclear-medicine unit (PET tracers and therapeutic isotopes), with >50% revenue growth in H1-2026 and full-year revenue set to double versus 2025 as several years of facility investment converts to sales. Inside it, AlphaNostics takes proprietary cancer candidates into human trials later this year. Management targets $150m of nuclear-medicine revenue by 2030 and models the unit at $40–100m of the 2031 group EBITDA — the division it claims the most visibility over. Not separately listed.
Renergen — ASP Isotopes' helium & LNG business (Virginia project, Free State, South Africa)
ASP Isotopes' helium & LNG business at Virginia, Free State — 3% helium versus 0.4% in US gas and 0.04% in Qatar, with 1P reserves about the size of the entire US federal helium reserve and a Cape shipping edge worth having when ~1% of a liquid cargo boils off per day. Phase 1 (70 mcf/d He + 2,500 GJ/d LNG) started up in the week of 20-AUG-2026: ~$27m revenue and ~$11m gross profit at $600/mcf, $15–20m of gross profit at the $800–1,000 now being negotiated. Phase 2 is 13× the size at ~$370m revenue / $300m gross profit, funded by $500m DFC + $250m Standard Bank and built turnkey over 44 months for first production in 2030. Contracts run 5–15 years indexed to South African PPI, 100% of LNG and 50–75% of helium committed. Not separately investable — exposure is via ASPI.
A single evidentiary mention, offered by ASP Isotopes' CEO as third-party corroboration that the medical-isotope bottleneck is real: Bristol Myers "recently announced delays to their phase three trials because of the isotope supply chain." No view expressed on the company or the stock.
Named in the same sentence as Bristol Myers — phase-3 trial delays attributed to isotope supply, cited by ASP Isotopes' CEO as independent evidence of the ytterbium-176 shortage rather than as any view on Eli Lilly itself.
Noble Africa — the Nasdaq helium vehicle (heard as "Endra" in the auto-transcript)
The Nasdaq vehicle ASP Isotopes intends to merge the helium asset into — announced in July, described by Mann as becoming "the first helium pure-play company listed on NASDAQ that's actually producing helium," and the designated home for the residual $250m equity raise, with ASPI retaining 89% and "any dilution" falling there. (The auto-transcript of the conference hears the name as "Endra"; the Red Chip readout names it Noble Africa.) A stated structure rather than a completed one: neutral until the listing documents confirm the mechanics.
Named only as the demand curve under ytterbium-176, not as a stock view: Novartis' radiopharmaceutical Pluvicto is doing $3–4bn a year with consensus at $6–8bn by 2030, and because its active isotope lutetium-177 has a half-life of days it must be manufactured weekly and cannot be stockpiled — which Mann puts at "probably a one-to-one relationship" between drug demand and Yb-176 demand, against a supply base where Russia is the only commercial enricher.
Quantum Leap Energy — ASP Isotopes' nuclear-fuels spin-out
ASP Isotopes' nuclear-fuels venture (HALEU, lithium-6/7, LEU+), to be spun out to ASPI holders on a ratio already decided but undisclosed and explicitly not one-for-one. The S-1 was filed in November and slipped through a four-to-six-week SEC shutdown and stale February financials into an April re-filing; after a share exchange for the convertible loan note Mann targets a spin-out "between now and the end of the year," barred before 13-Sep-2026 (IPO anniversary, US capital-gains reasons) and gated commercially on a Fermi contract that is "very close." Timing and mechanics only — no valuation attached.
In one line: the channel's research is converging on South African helium from two directions — D3 Energy (ASX: D3E / OTCQX: DNRGF), drilling ~A$200,000 wells into a $600+/mcf product on a 479,409-acre Virginia Fault position with verified helium up to 8%, and ASP Isotopes (Nasdaq: ASPI), whose Renergen plant a few kilometres away started up in the week of 20-AUG-2026 with a first helium contract already struck at $600/mcf on take-or-pay 5–15 year terms — the same corridor, the same price point, one explorer and one producer now in start-up. Two independent same-day reads on ASPI now sit in the archive: a member's readout of a private Red Chip call, and CEO Paul Mann's own conference presentation, which agree on every overlapping number.
ASP Isotopes is the newer and broader thread (2026-AUG-20, Frodsham2866's write-up of a ~10-person Red Chip call with CEO Paul Mann and Renergen COO Nick Mitchell). The parts reaching first revenue together: the Virginia helium/LNG plant in commissioning with first shipments due early September and 3/4 of Stage 1 output targeted for contract by end-September; silicon-28 at 99.5% against the 99.9995% quantum spec, with the far larger 99% market to be attacked anyway; ytterbium going continuous next month; PET Labs heading for $150m of nuclear-medicine revenue by 2030; and the QLE spin-out, barred before 13 September and gated on a Fermi contract that is "very close." Mann would not discuss price or valuation at all — "it's an investor's job to evaluate that" — so the 15× / $4.5–5bn by 2031 figure came from the attendees, not the company.
Management's own version of the same story is now archived beside it (2026-AUG-20, CEO Paul Mann at the Emerging Growth Conference, shared into the channel — a company presentation, so the Positive stance is the company's pitch, not a member's). It corroborates the Red Chip readout on every overlapping figure and adds the supply-shock arithmetic: helium is a $3bn market growing at GDP-plus; the US strategic reserve has fallen from ~a third of global supply to almost zero, taking price from ~$200 to $400–500/mcf; Qatar (~1/3 of supply) is shut in after Iranian damage to its gas processing with facilities "impaired for a number of years," and Russia (~15%) has imposed export controls — "almost 50% of the world's helium supply is currently not available," a fifth helium supply crisis, with Asian fabs worried about volume rather than price.
The Renergen numbers, from the operator: the asset runs 3% helium versus 0.4% in US gas and 0.04% in Qatar, with 1P reserves about the size of the entire US federal helium reserve and a shipping edge at the Cape (roughly 1% of a liquid cargo boils off per day). Phase 1 (70 mcf/d He + 2,500 GJ/d LNG) started up that week: ~$27m revenue / $11m gross profit at $600/mcf, rising to $15–20m of gross profit at the $800–1,000 now being negotiated (spot "north of $2,000," hearsay) — pure operating leverage on a fixed volume. Phase 2 is 13× the size (900 mcf/d + 34,000 GJ/d) at ~$370m revenue / $300m gross profit, funded by the $500m DFC + $250m Standard Bank debt, built turnkey over 44 months for first production in 2030. Contracts run 5–15 years indexed to South African PPI — 100% of LNG and 50–75% of helium committed, the balance left on spot deliberately.
The isotope side finally has a root cause and a scorecard. The Si-28 delay is bought-in hardware, not process physics: over 400 compressors from a Swiss supplier shipped with faulty O-rings, each rebuilt by hand in a clean room — 48 stages are enriching correctly today, 96–100 are needed for the quantum grade, giving 80 kg/yr at 99.995% plus several hundred kg at 99%, with a second plant (likely Iceland) buildable in ~12 months. Yb-176 reaches ~1 kg/yr once the continuous vessel is built in September, against a market where Russia is the only commercial enricher and demand tracks Novartis' Pluvicto ($3–4bn/yr → $6–8bn by 2030, ~100 radiotherapeutics in trials) roughly one-for-one — with Bristol Myers and Eli Lilly already blaming isotope supply for phase-3 delays. Per-gram prices: C-14 $24,000, Yb-176 $20,000, Si-28 a few hundred. Group guidance is $300m of EBITDA in 2031 (electronic gases 150–300, LNG 100–200, medical isotopes 40–100, radiopharma 40–100) — a headline that sits below the sum of its own low ends.
The ASPI funding gate is the checklist to track:$500m DFC + $250m Standard Bank released only on (1) Phase 1 at nameplate, (2) 50% of Stage 2 contracted, (3) no sales to China, North Korea, Iran or Russia — then a further $250m raised at Noble Africa, the intended Nasdaq helium vehicle, where "any dilution should fall," with ASPI retaining 89%. That last mechanism is asserted, not yet documented.
The framing voice on D3 Energy is William H. Hastings ("Bill"/"WHH"), a retired oil & gas executive whose emails are relayed to the channel with permission (he drilled the discovery well that led to Norway's ~700-million-barrel Alvheim field). He is "strongly positive" on D3, and his wellhead-only revenue matrix — price × content × volume, less wellhead OPEX, haircut for an 83% success rate, divided into well cost — puts payout at roughly one month before facility costs.
The asymmetry he keeps returning to: "we have a $600+/mcf product and on the other hand we have <$200,000 wells to get that." At that cost a dry hole is immaterial — it buys seismic calibration and reserve definition rather than destroying capital.
The value event is reclassification, not the drill bit. New well results plus the coming 2D seismic go to Sproule, and are expected to move volumes from Contingent to Proven/Probable/Possible — the classification that underpins the PR016 Production Right Application (which today covers only ~15% of ER315 and ~9% of total acreage).
What to watch, per Hastings: helium content >4%, pressure and flow on NGT245 E and D; the map of where the 2D seismic is shot (a forward map of the development); and two further wells this year positioned south toward the PRA to test whether the fault systems are pressure-connected.
The channel's temperament argument, from Frodsham2866: the pattern of delays and public management-bashing around ASPI "reminds me forcibly" of GB Group, a UK ID-software company he held for four years through two profit warnings and a 33p → 50p → 15p → 33p round trip before selling for a £2,500 gain — after which it ran to nearly 1000p, worth roughly £6m on his 600,000 shares. He is explicit it is an analogy and not a forecast: "you have to do your own work on it… and make your own mind up."
Curator view (Stephen, not a channel member): there appears to be little or no decline curve on these wells, with up to ~500,000 acres still subject to being proved up — which would suggest world-class potential in size and richness.
Attribution rule for this archive: this is a channel-level source. Every stance is the named member's, not the channel's — Bert (who reprints Bill's comments) and Nathan (who asked for the valuation matrix) appear as context, not as rated voices. Where a member relays management (as Frodsham2866 does from the Red Chip call), the operational facts are the company's and the stance is the member's — the two are kept separate on the dated page. And where the channel simply shares a company's own presentation (Paul Mann at the Emerging Growth Conference), the page is flagged as management framing throughout: the Positive stance on ASPI there is the company pitching itself, and is to be read as a set of dated, checkable claims rather than as channel conviction.
Posts
One dated page per archived post — each has its talking points and the saved source material. Newest first.